PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026HIV Medicine0 citations

Efficacy of dolutegravir/lamivudine in adults with HIV ‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results

View Full Paper
DFD. FoxViiV Healthcare (Spain)JSJ. SlimNew York Medical CollegeEOE.T. Overton

Key Points

  • This analysis aims to evaluate the efficacy and safety of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody.
  • Phase 3/3b study design
  • Assessment of HIV-1 suppression rates
  • Monitoring for HBV reactivation
  • Evaluation of safety signals
  • High rates of HIV-1 suppression observed
  • No cases of HBV reactivation reported
  • No new safety signals identified

Abstract

This analysis provides new information about DTG/3TC treatment for people with HIV-1 and isolated reactive anti-HBc. There were high rates of HIV-1 suppression with DTG/3TC, no cases of HBV reactivation and no new safety signals identified.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Fox et al. (2026) studied this question.

synapsesocial.com/papers/69e47282010ef96374d8e82bhttps://doi.org/10.1111/hiv.70237
Ask AI
Helpful
Bookmark
Share
View Full Paper